Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News SCYNEXIS Inc. SCYX

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor...

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:SCYX)

Fundamentals Snapshot (NDAQ:SCYX)

Current News (NDAQ:SCYX)

SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting

GlobeNewswire 4 days ago

SCYNEXIS Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME® (ibrexafungerp tablets) for Prevention of Recurrent Vaginal Yeast Infections

GlobeNewswire 7 days ago

SCYNEXIS Presents Positive Data from Phase 3 CANDLE Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the ISSVD XXVI World Congress and International Vulvovaginal Disease Update

GlobeNewswire July 19, 2022

SCYNEXIS to Present Data from the CANDLE Nested Sub-Study of Ibrexafungerp During the International Society for the Study of Vulvovaginal Disease (ISSVD) XXVI World Congress and International Vulvovaginal Disease Update

GlobeNewswire July 14, 2022

SCYNEXIS Announces Initiation of New Phase 3b Study (VANQUISH) to Evaluate Oral Ibrexafungerp as a Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole

GlobeNewswire June 23, 2022

SCYNEXIS Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections

GlobeNewswire June 8, 2022

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 3, 2022

SCYNEXIS to Present at Upcoming H.C. Wainwright Global Investment Conference

GlobeNewswire May 20, 2022

SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 12, 2022

Opinion & Analysis (NDAQ:SCYX)

No current opinion is available.

Bullboard Posts (NDAQ:SCYX)

Can we expect additional Rx's to the fold this winter?

It's been a while and I've had some time to digest several variables; here are some of my findings: These guys are still trading...
JonathanJSmith - 6 days ago

RE:RE:RE:RE:BREXAFEMME - published User side effects

I'm disgusted too. What does $45MM get them, another quarter's worth of financing - maybe two? One would think that they'd...
JonathanJSmith - April 26, 2022

RE:RE:RE:BREXAFEMME - published User side effects

I was going to sell at a loss, but decided to lower my average cost due to the discount. They will have $150M cash less Q1 spend...
dmacd - April 22, 2022

RE:RE:BREXAFEMME - published User side effects

Yeah, I agree - worse sales than I had expected. They should get a pop however when they submit their supplemental NDA vis-a-vis rVVC in...
JonathanJSmith - March 31, 2022

RE:BREXAFEMME - published User side effects

The problem is Mario and Christine are spending with reckless abandon. We need a businessman to run the company not a doctor. Mario can...
dmacd - March 29, 2022

BREXAFEMME - published User side effects

Join me by taking your action by contacting SCYX Investor Relations.   Today, I emailed Irina of SCYX - Investor Relations...
GMA133 - February 7, 2022